SynGen Inc. Expands its Management Team
Chuck Novak, VP and CFO, Paul Hoseit, Senior VP of R&D, and Barbara Fullmer, Senior Director of Quality Affairs assisting SynGen in the commercialization of its new products.
Sacramento, CA, April 27, 2015 – SynGen Inc., a company that focuses on the development and commercialization of instrument systems that harvest stem and progenitor cells from umbilical cord blood, bone marrow, peripheral blood, and cell culture, announced today that it has added three new members to its management team as its Cell Processing and Cord Blood Business Units focus on product commercialization.
Chuck Novak joins the management team as its Vice President and Chief Financial Officer. Chuck was most recently CFO at ConQuip in Rancho Cordova, CA, where he was named 2014 CFO of the Year by the Sacramento Business Journal. Chuck’s background includes over 40 years of financial, administrative and operational management experience with both small and large corporations, including positions of increasing authority during 16 years with Hewlett Packard.
Paul Hoseit joins the management team as the Senior Vice President of Research and Development. Paul has over 29 years of experience in developing electronic and imaging products, including 15 years of medical device product development and commercialization experience. His background includes 14 years at Volcano Corporation in Rancho Cordova, where his last position was Vice President System Research and Development.
Barbara Fullmer joins the management team as the Senior Director of Quality Affairs. Barbara brings over 27 years of experience in the high technology industry. She was a key member of the team that created the first medical device for Intel’s Digital Health Group, and was instrumental in the development of Intel’s Quality Management System. Barbara’s background also includes experience working at Affymetrix, Coherent Lasers, and NEC Electronics.
“We are delighted to have Chuck, Paul, and Barbara join the SynGen team,” said William Gerber, SynGen’s President and Chief Executive Officer. “Their combined experience, reputation, skills and insight will help SynGen refine its strategy, accelerate product introductions and meet new challenges as we address the needs of our customers in the cell processing and cord blood banking markets.”